Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314500 | 0.89 | TP53 (0.44) | SMN1; SMN2TP53MAPTKMOTHRB | |
| SCHEMBL25868000 | 0.84 | KMO (0.44) | SMN1; SMN2TP53MAPTKMOTSPO | |
| SCHEMBL22314474 | 0.81 | KMO (0.46) | SMN1; SMN2TP53MAPTKMOTSPO | |
| SCHEMBL25865015 | 0.77 | TP53 (0.47) | SMN1; SMN2TP53MAPTKMOTHRB | |
| SCHEMBL25868217 | 0.76 | MAPT (0.46) | SMN1; SMN2TP53MAPTKMOTHRB | |
| SCHEMBL22314498 | 0.76 | MAPT (0.53) | SMN1; SMN2TP53MAPTKMOTHRB | |
| SCHEMBL25868838 | 0.74 | TMEM97 (0.39) | SMN1; SMN2TP53MAPTKMOTHRB | |
| SCHEMBL25865022 | 0.74 | ALDH1A1 (0.46) | SMN1; SMN2TP53MAPTKMOTHRB | |
| SCHEMBL22314479 | 0.74 | KMO (0.63) | KMOTSPO | |
| SCHEMBL25868038 | 0.74 | ALDH1A1 (0.46) | SMN1; SMN2TP53MAPTKMOTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SMN1; SMN2 334/4885TP53 4487/4885MAPT 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.